Skip to main content
HANALL BIOPHARMA CO.,LTD logo

HANALL BIOPHARMA CO.,LTD — Investor Relations & Filings

Ticker · 009420 ISIN · KR7009420001 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2025-10-29 Transaction in Own Shar…
Country KR South Korea
Listing KO 009420

About HANALL BIOPHARMA CO.,LTD

http://www.hanallbiopharma.com/

HanAll Biopharma is a global biopharmaceutical company focused on developing innovative, first-in-class therapies for patients with unmet medical needs. The company's research and development efforts are centered on immunology, ophthalmology, and immuno-oncology, with a specialization in antibody-based therapeutics. Its pipeline includes novel treatments for autoimmune diseases and dry eye disease. The company's mission is to pioneer cutting-edge medicines that address incurable and immune-associated conditions. Alongside its innovative pipeline, HanAll Biopharma also operates a portfolio of pharmaceutical products in therapeutic areas including endocrine, circulatory, and urologic diseases.

Recent filings

Filing Released Lang Actions
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 95% confidence The document is titled '주요사항보고서(자기주식 처분 결정)' which translates to 'Material Event Report (Decision on Disposal of Treasury Shares)'. It is addressed to the Financial Services Commission and Korea Exchange, indicating a regulatory filing. The content details the decision to dispose of treasury shares, including quantities, prices, dates, and methods of disposal. It also references previous treasury share acquisitions and disposals. The document length is 2879 characters, which is relatively short and focused on a specific event rather than a comprehensive financial report. This matches the characteristics of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares. There is no indication that this is an announcement of a report publication or a certification, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2025-10-29 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a preliminary (잠정) earnings announcement based on consolidated financial statements for the period 2025-07-01 to 2025-09-30 (3rd quarter). It provides summarized financial results such as sales, operating profit, and net income, with comparisons to previous quarters and the same period last year. The document explicitly states it is a preliminary earnings disclosure (공정공시) prepared under Korean IFRS and notes that the figures are subject to change after external audit. The length is about 2311 characters, which is relatively short and typical for an earnings release rather than a full interim report. It contains key financial highlights but not detailed financial statements or comprehensive analysis. Therefore, this document fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. 9M 2025
2025-10-29 Korean
수시공시의무관련사항(공정공시)
Regulatory Filings Classification · 95% confidence The document is a short disclosure related to a mid-to-long-term dividend policy proposal by the company, intended to enhance shareholder value. It is a regulatory announcement about the establishment of a dividend policy, including its purpose, expected duration, and conditions. The document is brief (1014 characters) and does not contain actual financial statements or detailed financial data. It is not an annual or interim report, earnings release, or any detailed financial report. It is a regulatory announcement about a policy, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a general regulatory disclosure.
2025-10-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It includes detailed information about securities ownership, changes in holdings, and related data for an individual named 정승원, who is an executive (임원) of the company 한올바이오파마(주). The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange, indicating it is a formal regulatory filing. The content focuses on insider share ownership and transactions, not on financial results, management changes, or other report types. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 2437 characters, which is consistent with a detailed insider transaction report rather than a full financial report or announcement. Therefore, the correct classification is DIRS with high confidence.
2025-10-29 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is titled '최대주주등소유주식변동신고서' which translates to 'Major Shareholding Change Report'. It details changes in share ownership by major shareholders, including specific share counts before and after the change, dates, and individual shareholder information. There is no financial performance data, audit information, or management discussion. The content strictly relates to changes in significant share ownership levels, matching the definition of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming it is not a full report or announcement of a report but a direct notification of shareholding changes.
2025-10-29 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is titled '자기주식처분결과보고서' which translates to 'Report on Disposal of Treasury Shares'. It details the disposal of the company's own shares, including dates, quantities, prices, and post-disposal holdings. The document is a formal report submitted to the financial supervisory authority (금융감독원장 귀하). The content focuses on the company's transactions involving its own shares rather than financial results, management changes, or other report types. According to the filing definitions, reports about the company buying back or selling its own shares fall under 'Transaction in Own Shares' (POS). The document length is 1665 characters, which is short but contains substantive data about the share disposal, so it is not merely an announcement but a report of the transaction itself.
2025-10-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.